New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export KARD’s income statement to Excel — free account
KARDIGAN INC
KARD- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
11.54
0.98
−7.83%
After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.
Follow KARD
Alert me
KARDIGAN INC (KARD) P/E ratio
KARDIGAN INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SVRA Savara Inc. compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| KARD KARDIGAN INC | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 21.7× |
| Market median | 16.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)